We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
- Authors
Kantarjian, Hagop M.; Jabbour, Elias J.; Garcia‐Manero, Guillermo; Kadia, Tapan M.; DiNardo, Courtney D.; Daver, Naval G.; Borthakur, Gautam; Jain, Nitin; Waukau, Jane B.; Kwari, Monica I.; Ravandi, Farhad; Anderson, Barry D.; Iizuka, Kenzo; Jin, Cheng; Zhang, Chun; Plunkett, William K.; Garcia-Manero, Guillermo
- Abstract
<bold>Background: </bold>DFP-10917, a deoxycytidine nucleoside analogue, has a unique mechanism of action resulting in leukemic cell death when administered for prolonged periods at low doses. The current phase 1/2 study investigated the safety, maximum tolerated dose, and evidence of antileukemic activity for DFP-10917 administered by 7-day or 14-day continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia (AML).<bold>Methods: </bold>In the phase 1 dose escalation portion of the study, patients were administered DFP-10917 by 7-day continuous intravenous infusion plus 21-day rest (stage 1) or 14-day continuous intravenous infusion plus 14-day rest (stage 2). The primary objectives of phase 1 were to determine the maximum tolerated dose, the phase 2 dose, and the dose-limiting toxicities (DLTs) of DFP-10917. The primary objectives of phase 2 were to evaluate the overall response rate of DFP-10917 using complete response (CR), CR without platelet recovery (CRp), CR with incomplete blood count recovery (CRi) or partial response.<bold>Results: </bold>In stage 1 of phase 1 (4-35 mg/m2 /day as a 7-day continuous intravenous infusion), a DLT of grade 3 diarrhea occurred at a dose of 35 mg/m2 /day. In stage 2 of phase 1, a dose of 10 mg/m2 /day as a 14-day continuous intravenous infusion resulted in DLTs of prolonged hypocellularity, abdominal pain, diarrhea, and vomiting. The dose of 6 mg/m2 /day as a 14-day continuous intravenous infusion was found to be well tolerated and was selected for phase 2. Response rates in patients in phase 2 (N = 29) were 20.7% CR, 3.4% CRp, and 24.1% CRi. The overall response rate was 48.3% (95% confidence interval, 29.4%-67.5%).<bold>Conclusions: </bold>DFP-10917 as a 14-day continuous intravenous infusion at a dose of 6 mg/m2 /day can be administered safely and appears to be effective in patients with recurrent or refractory AML. A phase 3 investigation comparing DFP-10917 monotherapy versus standard of care in an early recurrent or refractory AML setting is warranted.
- Subjects
ACUTE myeloid leukemia; INTRAVENOUS therapy; BONE marrow
- Publication
Cancer (0008543X), 2019, Vol 125, Issue 10, p1665
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.31923